Table 3. Variables Associated With Kidney Outcome Within 12 Months.

	No. of Patients	No. of Events	Bivariable Analysis		Multivariable Analysis
			Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
Age group, y
65	63	30	1 [Reference]	.72
≥65	31	16	0.85 (0.36-2.02)
Monoclonal gammopathy of undetermined significance
No preexisting	76	38	1 [Reference]	.67
Preexisting	18	8	0.80 (0.28-2.25)
Chronic kidney disease
No preexisting	83	40	1 [Reference]	.69
Preexistinga	11	6	1.29 (0.36-4.56)
Type of myelomab
Light chain	45	16	1 [Reference]	.02	1 [Reference]	.03
Whole immunoglobulin	49	30	2.62 (1.14-6.05)		2.75 (1.11-6.80)
Light chain isotype
κ	51	24	1 [Reference]	.69
λ	43	22	1.18 (0.52-2.66)
Cytogenetics
Standard risk	46	23	1 [Reference]	>.99
High riskc	12	6	1.00 (0.28-3.56)
Baseline serum-free light chain level, mg/Ld
<3000	20	13	1 [Reference]
3000-5999	26	11	0.39 (0.12-1.32)	.13
6000-11 999	17	10	0.77 (0.20-2.92)	.70
≥12 000	18	12	0.40 (0.12-1.32)	.13
After first chemotherapy cycle, level of involved serum-free light chain, mg/Le
>500	59	23	1 [Reference]	.01	1 [Reference]	.049
≤500	35	23	3.00 (1.25-7.18)		2.51 (1.00-6.33)
Randomization groupf
Conventional hemodialysis	48	18	1 [Reference]	.02	1 [Reference]	.03
High-cutoff hemodialysis	46	28	2.59 (1.13-5.97)		2.78 (1.13-6.80)

^aDefined by an estimated glomerular filtration rate of 30 mL/min/1.73 m² or greater.

^bAt baseline, the median serum-free light chain level was 7627 mg/L (interquartile range, 3564-14 110 mg/L) in patients with light chain myeloma and was 5040 mg/L (interquartile range, 2505-12 425 mg/L) in patients with whole immunoglobulin myeloma (P = .16).

^cPresence of t(4;14), Del17p, or both.

^dMissing data for 3 patients.

^eMissing data (n = 6) were imputed by the modal class (no reduction).

^fAdjusted for myeloma subtype (whole immunoglobulin or myeloma-secreting light chain only) and serum-free light chain level reduction of 500 mg/L or less.